Targeting the pleiotrophin/receptor protein tyrosine phosphatase β/ ζ signaling pathway to limit neurotoxicity induced by drug abuse

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 440-447

  Herradón, Gonzalo ^a   Ezquerra, Laura ^a   Gramage, Esther ^a   Alguacil, Luis F ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Cocaine; Drug development; Drug discovery; Midkine; Neurodegeneration; Parkinson's disease; Pleiotrophin; RPTP

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA CATENIN; COCAINE; ISIS 113715; NERVE CELL ADHESION MOLECULE; PLEIOTROPHIN; PROTEIN KINASE C; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; SYNDECAN 3; CARRIER PROTEIN; CYTOKINE; STREET DRUG;

BINDING AFFINITY; CELL STRAIN; CELL SURVIVAL; DRUG ABUSE; DRUG DEPENDENCE; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; INHIBITION KINETICS; NERVE CELL; NERVE FIBER GROWTH; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ADDICTION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; PHYSIOLOGY; TOXICITY AND INTOXICATION;

ANIMALS; CARRIER PROTEINS; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; NEUROTOXICITY SYNDROMES; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; SIGNAL TRANSDUCTION; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 67549108377     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787847895     Document Type: Review

References (107)

1. Weiss, F.; Koob, G.F. Drug addiction: functional neurotoxicity of the brain reward systems. Neurotox. Res., 2001, 3, 145-56.
2. Thomas, D.M.; Walker, P.D.; Benjamins, J.A.; Geddes, T.J.; Kuhn, D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther., 2004, 311, 1-7.
3. Riddle, E.L.; Fleckenstein, A.E.; Hanson, G.R. Role of monoamine transporters in mediating psychostimulant effects. AAPS J., 2005, 7, E847-51.
4. Pothos, E.N. Regulation of dopamine quantal size in midbrain and hippocampal neurons. Behav. Brain Res., 2002, 130, 203-7.
5. Kalivas, P.W.; O'Brien, C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology, 2008, 33, 166-80.
6. Hyman, S.E.; Malenka, R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev. Neurosci., 2001, 2, 695-703.
7. Przedborski, S.; Vila, M. The last decade in Parkinson's disease research. Basic sciences. Adv. Neurol., 2001, 86, 177-86.
8. Fahn, S.; Sulzer, D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx., 2004, 1, 139-54.
9. Ziolkowska, B.; Gieryk, A.; Bilecki, W.; Wawrzczak-Bargiela, A.; Wedzony, K.; Chocyk, A.; Danielson, P.E.; Thomas, E.A.; Hilbush, B.S.; Sutcliffe, J.G.; Przewlocki, R. Regulation of alpha-synuclein expression in limbic and motor brain regions of morphine-treated mice. J. Neurosci., 2005, 25, 4996-5003.
10. Qin, Y.; Ouyang, Q.; Pablo, J.; Mash, D.C. Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. Neuroreport, 2005, 16, 1489-93.
11. Mash, D.C.; Ouyang, Q.; Pablo, J.; Basile, M.; Izenwasser, S.; Lieberman, A.; Perrin, R.J. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J. Neurosci., 2003, 23, 2564-71.
12. Eriksen, J.L.; Wszolek, Z.; Petrucelli, L. Molecular pathogenesis of Parkinson disease. Arch. Neurol., 2005, 62, 353-7.
13. Bannon, M.J. The dopamine transporter: role in neurotoxicity and human disease. Toxicol. Appl. Pharmacol., 2005, 204, 355-60.
14. Kulkarni, V.A.; Jha, S.; Vaidya, V.A. Depletion of norepinephrine decreases the proliferation, but does not influence the survival and differentiation, of granule cell progenitors in the adult rat hippocampus. Eur. J. Neurosci., 2002, 16, 2008-12.
15. Alguacil, L.F.; Morales, L. Alpha-2 adrenoceptor ligands and opioid drugs: pharmacological interactions of therapeutic interest. Curr. Neuropharmacol., 2004, 2, 343-352.
16. Milner, P.G.; Li, Y.S.; Hoffman, R.M.; Kodner, C.M.; Siegel, N.R.; Deuel, T.F. A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem. Biophys. Res. Commun., 1989, 165, 1096-103.
17. Rauvala, H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J., 1989, 8, 2933-41.
18. Li, Y.S.; Milner, P.G.; Chauhan, A.K.; Watson, M.A.; Hoffman, R M.; Kodner, C M.; Milbrandt, J.; Deuel, T.F. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science, 1990, 250, 1690-4.
19. Li, Y.S.; Hoffman, R.M.; Le Beau, M.M.; Espinosa, R., 3rd; Jenkins, N.A.; Gilbert, D.J.; Copeland, N.G.; Deuel, T.F. Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization. J. Biol. Chem., 1992, 267, 26011-6.
20. Deuel, T.F.; Zhang, N.; Yeh, H.J.; Silos-Santiago, I.; Wang, Z.Y. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch. Biochem. Biophys., 2002, 397, 162-71.
21. Chauhan, A.K.; Li, Y.S.; Deuel, T.F. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc. Natl. Acad. Sci. U S A., 1993, 90, (2), 679-82.
22. Brunet-de Carvalho, N.; Raulais, D.; Rauvala, H.; Souttou, B.; Vigny, M. HB-GAM/Pleiotrophin and Midkine are differently expressed and distributed during retinoic acid-induced neural differentiation of P19 cells. Growth Factors, 2003, 21, 139-49.
23. Yeh, H.J.; He, Y.Y.; Xu, J.; Hsu, C.Y.; Deuel, T.F. Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. J. Neurosci., 1998, 18, 3699-707.
24. Vanderwinden, J.M.; Mailleux, P.; Schiffmann, S.N.; Vanderhaeghen, J.J. Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat. Embryol (Berl)., 1992, 186, 387-406.
25. Li, Y.S.; Gurrieri, M.; Deuel, T.F. Pleiotrophin gene expression is highly restricted and is regulated by platelet-derived growth factor. Biochem. Biophys. Res. Commun., 1992, 184, 427-32.
26. Silos-Santiago, I.; Yeh, H.J.; Gurrieri, M.A.; Guillerman, R.P.; Li, Y.S.; Wolf, J.; Snider, W.; Deuel, T.F. Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neural-glial interactions during development and in maturity. J. Neurobiol., 1996, 31, 283-96.
27. Hienola, A.; Pekkanen, M.; Raulo, E.; Vanttola, P.; Rauvala, H. HB-GAM inhibits proliferation and enhances differentiation of neural stem cells. Mol. Cell. Neurosci., 2004, 26, 75-88.
28. Jung, C.G.; Hida, H.; Nakahira, K.; Ikenaka, K.; Kim, H.J.; Nishino, H. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells. FASEB J., 2004, 18, 1237-9.
29. Sakakima, H.; Yoshida, Y.; Kadomatsu, K.; Yuzawa, Y.; Matsuo, S.; Muramatsu, T. Midkine expression in rat spinal motor neurons following sciatic nerve injury. Brain. Res. Dev. Brain. Res., 2004, 153, 251-60.
30. Kikuchi-Horie, K.; Kawakami, E.; Kamata, M.; Wada, M.; Hu, J.G.; Nakagawa, H.; Ohara, K.; Watabe, K.; Oyanagi, K. Distinctive expression of midkine in the repair period of rat brain during neurogenesis: immunohistochemical and immunoelectron microscopic observations. J. Neurosci. Res., 2004, 75, 678-87.
31. Ezquerra, L.; Alguacil, L.F.; Nguyen, T.; Deuel, T.F.; Silos-Santiago, I.; Herradon, G. Different pattern of pleiotrophin and midkine expression in neuropathic pain: correlation between changes in pleiotrophin gene expression and rat strain differences in neuropathic pain. Growth Factors, 2008, 26, 44-8.
32. Blondet, B.; Carpentier, G.; Lafdil, F.; Courty, J. Pleiotrophin cellular localization in nerve regeneration after peripheral nerve injury. J. Histochem. Cytochem., 2005, 53, 971-7.
33. Rauvala, H.; Peng, H.B. HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Prog. Neurobiol., 1997, 52, 127-44.
34. Iseki, K.; Hagino, S.; Mori, T.; Zhang, Y.; Yokoya, S.; Takaki, H.; Tase, C.; Murakawa, M.; Wanaka, A. Increased syndecan expression by pleiotrophin and FGF receptor-expressing astrocytes in injured brain tissue. Glia, 2002, 39, 1-9.
35. Dugas, J.C.; Mandemakers, W.; Rogers, M.; Ibrahim, A.; Daneman, R.; Barres, B.A. A novel purification method for CNS projection neurons leads to the identification of brain vascular cells as a source of trophic support for corticospinal motor neurons. J. Neurosci., 2008, 28, 8294-305.
36. Mourlevat, S.; Debeir, T.; Ferrario, J.E.; Delbe, J.; Caruelle, D.; Lejeune, O.; Depienne, C.; Courty, J.; Raisman-Vozari, R.; Ruberg, M. Pleiotrophin mediates the neurotrophic effect of cyclic AMP on dopaminergic neurons: analysis of suppression-subtracted cDNA libraries and confirmation in vitro. Exp. Neurol., 2005, 194, 243-54.
37. Marchionini, D.M.; Lehrmann, E.; Chu, Y.; He, B.; Sortwell, C.E.; Becker, K.G.; Freed, W.J.; Kordower, J.H.; Collier, T.J. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res., 2007, 1147, 77-88.
38. Hida, H.; Jung, C.G.; Wu, C.Z.; Kim, H.J.; Kodama, Y.; Masuda, T.; Nishino, H. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur. J. Neurosci., 2003, 17, 2127-34.
39. Hida, H.; Masuda, T.; Sato, T.; Kim, T.S.; Misumi, S.; Nishino, H. Pleiotrophin promotes functional recovery after neural transplantation in rats. Neuroreport, 2007, 18, 179-83.
40. Moses, D.; Drago, J.; Teper, Y.; Gantois, I.; Finkelstein, D.I.; Horne, M.K. Fetal striatum- and ventral mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo. Neuroscience, 2008, 154, 606-20.
41. Mi, R.; Chen, W.; Hoke, A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc. Natl. Acad. Sci. U S A., 2007, 104, 4664-9.
42. Christman, K.L.; Fang, Q.; Kim, A.J.; Sievers, R.E.; Fok, H.H.; Candia, A.F.; Colley, K.J.; Herradon, G.; Ezquerra, L.; Deuel, T.F.; Lee, R.J. Pleiotrophin induces formation of functional neovasculature in vivo. Biochem. Biophys. Res. Commun., 2005, 332, 1146-52.
43. Meng, K.; Rodriguez-Pena, A.; Dimitrov, T.; Chen, W.; Yamin, M.; Noda, M.; Deuel, T.F. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl. Acad. Sci. USA, 2000, 97, 2603-8.
44. Maeda, N.; Nishiwaki, T.; Shintani, T.; Hamanaka, H.; Noda, M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/ heparin-binding growth-associated molecule (HB-GAM). J. Biol. Chem., 1996, 271, 21446-52.
45. Kaplan, R.; Morse, B.; Huebner, K.; Croce, C.; Howk, R.; Ravera, M.; Ricca, G.; Jaye, M.; Schlessinger, J. Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain. Proc. Natl. Acad. Sci. USA, 1990, 87, 7000-4.
46. Krueger, N.X.; Streuli, M.; Saito, H. Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. Embo J., 1990, 9, 3241-52.
47. Krueger, N.X.; Saito, H. A human transmembrane protein-tyrosinephosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc. Natl. Acad. Sci. USA, 1992, 89, 7417-21.
48. Maeda, N.; Hamanaka, H.; Shintani, T.; Nishiwaki, T.; Noda, M. Multiple receptor-like protein tyrosine phosphatases in the form of chondroitin sulfate proteoglycan. FEBS Lett., 1994, 354, 67-70.
49. Weiss, A.; Schlessinger, J. Switching signals on or off by receptor dimerization. Cell, 1998, 94, 277-80.
50. Majeti, R.; Bilwes, A.M.; Noel, J.P.; Hunter, T.; Weiss, A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science, 1998, 279, 88-91.
51. Desai, D.M.; Sap, J.; Schlessinger, J.; Weiss, A. Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell, 1993, 73, 541-54.
52. Bilwes, A.M.; den Hertog, J.; Hunter, T.; Noel, J.P. Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization. Nature, 1996, 382, 555-9.
53. Fukada, M.; Fujikawa, A.; Chow, J.P.; Ikematsu, S.; Sakuma, S.; Noda, M. Protein tyrosine phosphatase receptor type Z is inactivated by ligand-induced oligomerization. FEBS Lett., 2006, 580, 4051-6.
54. Kawachi, H.; Fujikawa, A.; Maeda, N.; Noda, M. Identification of GIT1/ Cat-1 as a substrate molecule of protein tyrosine phosphatase zeta/beta by the yeast substrate-trapping system. Proc. Natl. Acad. Sci. USA, 2001, 98, 6593-8.
55. Fukada, M.; Kawachi, H.; Fujikawa, A.; Noda, M. Yeast substratetrapping system for isolating substrates of protein tyrosine phosphatases: Isolation of substrates for protein tyrosine phosphatase receptor type z. Methods, 2005, 35, 54-63.
56. Pariser, H.; Ezquerra, L.; Herradon, G.; Perez-Pinera, P.; Deuel, T.F. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem. Biophys. Res. Commun., 2005, 332, 664-9.
57. Pariser, H.; Perez-Pinera, P.; Ezquerra, L.; Herradon, G.; Deuel, T.F. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta. Biochem. Biophys. Res. Commun., 2005, 335, 232-9.
58. Pariser, H.; Herradon, G.; Ezquerra, L.; Perez-Pinera, P.; Deuel, T.F. Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C. Proc. Natl. Acad. Sci. USA, 2005, 102, 12407-12.
59. Stoica, G.E.; Kuo, A.; Aigner, A.; Sunitha, I.; Souttou, B.; Malerczyk, C.; Caughey, D.J.; Wen, D.; Karavanov, A.; Riegel, A.T.; Wellstein, A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem., 2001, 276, 16772-9.
60. Perez-Pinera, P.; Zhang, W.; Chang, Y.; Vega, J.A.; Deuel, T.F. Anaplastic lymphoma kinase is activated through the pleiotrophin/ receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J. Biol. Chem., 2007, 282, 28683-90.
61. Raulo, E.; Chernousov, M.A.; Carey, D.J.; Nolo, R.; Rauvala, H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J. Biol. Chem., 1994, 269, 12999-3004.
62. Levy, J.B.; Canoll, P.D.; Silvennoinen, O.; Barnea, G.; Morse, B.; Honegger, A. M.; Huang, J.T.; Cannizzaro, L.A.; Park, S.H.; Druck, T. The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J. Biol. Chem., 1993, 268, 10573-81.
63. Herradon, G.; Ezquerra, L.; Nguyen, T.; Vogt, T.F.; Bronson, R.; Silos-Santiago, I.; Deuel, T.F. Pleiotrophin is an important regulator of the renin-angiotensin system in mouse aorta. Biochem. Biophys. Res. Commun., 2004, 324, 1041-7.
64. Ezquerra, L.; Herradon, G.; Nguyen, T.; Vogt, T.F.; Bronson, R.; Silos-Santiago, I.; Deuel, T.F. Pleiotrophin is a major regulator of the catecholamine biosynthesis pathway in mouse aorta. Biochem. Biophys. Res. Commun., 2004, 323, 512-7.
65. Ezquerra, L.; Herradon, G.; Nguyen, T.; Silos-Santiago, I.; Deuel, T.F. Midkine is a potent regulator of the catecholamine biosynthesis pathway in mouse aorta. Life Sci., 2006, 79, 1049-55.
66. Ezquerra, L.; Herradon, G.; Nguyen, T.; Silos-Santiago, I.; Deuel, T.F. Midkine, a newly discovered regulator of the reninangiotensin pathway in mouse aorta: significance of the pleiotrophin/midkine developmental gene family in angiotensin II signaling. Biochem. Biophys. Res. Commun., 2005, 333, 636-43.
67. Kadomatsu, K.; Muramatsu, T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett., 2004, 204, 127-43.
68. Herradon, G.; Ezquerra, L.; Nguyen, T.; Silos-Santiago, I.; Deuel, T.F. Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/midkine developmental gene family. Biochem. Biophys. Res. Commun., 2005, 333, 714-21.
69. Ezquerra, L., Herradon, G., Nguyen, T., Silos-Santiago, I., Deuel, T.F. Pleiotrophin regulates tyrosine hydroxylase gene expression in mouse nervous system. Program No. 1006.13. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online. 2005.
70. Gramage, E.; Alguacil, L.F.; Herradon, G. Pleiotrophin prevents cocaine-induced toxicity in vitro. Eur. J. Pharmacol., 2008, 595, 35-8.
71. Le Greves, P. Pleiotrophin gene transcription in the rat nucleus accumbens is stimulated by an acute dose of amphetamine. Brain Res. Bull., 2005, 65, 529-32.
72. Mailleux, P.; Preud'homme, X.; Albala, N.; Vanderwinden, J.M.; Vanderhaeghen, J.J. Delta-9-Tetrahydrocannabinol regulates gene expression of the growth factor pleiotrophin in the forebrain. Neurosci. Lett., 1994, 175, 25-7.
73. Ezquerra, L.; Perez-Garcia, C.; Garrido, E.; Diez-Fernandez, C.; Deuel, T.F.; Alguacil, L.F.; Herradon, G. Morphine and yohimbine regulate midkine gene expression in the rat hippocampus. Eur. J. Pharmacol., 2007, 557, 147-50.
74. Flatscher-Bader, T.; Wilce, P.A. Impact of Alcohol Abuse on Protein Expression of Midkine and Excitatory Amino Acid Transporter 1 in the Human Prefrontal Cortex. Alcohol Clin. Exp. Res., 2008, 32, 1849-58.
75. Flatscher-Bader, T.; Wilce, P. A. Chronic smoking and alcoholism change expression of selective genes in the human prefrontal cortex. Alcohol Clin. Exp. Res., 2006, 30, 908-15.
76. Alonso, E.; Garrido, E.; Diez-Fernandez, C.; Perez-Garcia, C.; Herradon, G.; Ezquerra, L.; Deuel, T.F.; Alguacil, L.F. Yohimbine prevents morphine-induced changes of glial fibrillary acidic protein in brainstem and alpha2-adrenoceptor gene expression in hippocampus. Neurosci. Lett., 2007, 412, 163-7.
77. Cunha-Oliveira, T.; Rego, A.C.; Morgadinho, M.T.; Macedo, T.; Oliveira, C.R. Differential cytotoxic responses of PC12 cells chronically exposed to psychostimulants or to hydrogen peroxide. Toxicology, 2006, 217, 54-62.
78. Kadota, T.; Yamaai, T.; Saito, Y.; Akita, Y.; Kawashima, S.; Moroi, K.; Inagaki, N.; Kadota, K. Expression of dopamine transporter at the tips of growing neurites of PC12 cells. J. Histochem. Cytochem., 1996, 44, 989-96.
79. Perez-Pinera, P.; Alcantara, S.; Dimitrov, T.; Vega, J.A.; Deuel, T.F. Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. USA, 2006, 103, 17795-800.
80. Castelo-Branco, G.; Wagner, J.; Rodriguez, F.J.; Kele, J.; Sousa, K.; Rawal, N.; Pasolli, H.A.; Fuchs, E.; Kitajewski, J.; Arenas, E. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl. Acad. Sci. USA, 2003, 100, 12747-52.
81. Kitagawa, H.; Ray, W.J.; Glantschnig, H.; Nantermet, P.V.; Yu, Y.; Leu, C.T.; Harada, S.; Kato, S.; Freedman, L.P. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol. Cell. Biol., 2007, 27, 7486-96.
82. Liu, C.; Wang, Y.; Smallwood, P.M.; Nathans, J. An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus. J. Neurosci., 2008, 28, 5641-53.
83. Lynch, W.J.; Girgenti, M.J.; Breslin, F.J.; Newton, S.S.; Taylor, J.R. Gene profiling the response to repeated cocaine self-administration in dorsal striatum: a focus on circadian genes. Brain Res., 2008, 1213, 166-77.
84. Newton, P.M.; Ron, D. Protein kinase C and alcohol addiction. Pharmacol. Res., 2007, 55, 570-7.
85. Proctor, W.R.; Poelchen, W.; Bowers, B.J.; Wehner, J.M.; Messing, R.O.; Dunwiddie, T.V. Ethanol differentially enhances hippocampal GABA A receptor-mediated responses in protein kinase C gamma (PKC gamma) and PKC epsilon null mice. J. Pharmacol. Exp. Ther., 2003, 305, 264-70.
86. Hodge, C.W.; Mehmert, K.K.; Kelley, S.P.; McMahon, T.; Haywood, A.; Olive, M.F.; Wang, D.; Sanchez-Perez, A.M.; Messing, R.O. Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKCepsilon. Nat. Neurosci., 1999, 2, 997-1002.
87. Harris, R.A.; McQuilkin, S.J.; Paylor, R.; Abeliovich, A.; Tonegawa, S.; Wehner, J.M. Mutant mice lacking the gamma isoform of protein kinase C show decreased behavioral actions of ethanol and altered function of gamma-aminobutyrate type A receptors. Proc. Natl. Acad. Sci. USA, 1995, 92, 3658-62.
88. Slevin, J.T.; Gerhardt, G.A.; Smith, C.D.; Gash, D.M.; Kryscio, R.; Young, B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg., 2005, 102, 216-22.
89. Nutt, J.G.; Burchiel, K.J.; Comella, C.L.; Jankovic, J.; Lang, A.E.; Laws, E.R., Jr.; Lozano, A.M.; Penn, R.D.; Simpson, R.K., Jr.; Stacy, M.; Wooten, G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 2003, 60, 69-73.
90. Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A.; Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P.; Brodsky, M.A.; Burchiel, K.; Kelly, P.; Dalvi, A.; Scott, B.; Stacy, M.; Turner, D.; Wooten, V.G.; Elias, W.J.; Laws, E.R.; Dhawan, V.; Stoessl, A.J.; Matcham, J.; Coffey, R.J.; Traub, M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 2006, 59, 459-66.
91. Harroch, S.; Palmeri, M.; Rosenbluth, J.; Custer, A.; Okigaki, M.; Shrager, P.; Blum, M.; Buxbaum, J.D.; Schlessinger, J. No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta. Mol Cell Biol., 2000, 20, 7706-15.
92. Tonks, N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell. Biol., 2006, 7, 833-46.
93. Ostman, A.; Hellberg, C.; Bohmer, F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer, 2006, 6, 307-20.
94. Hendriks, W.J.; Elson, A.; Harroch, S.; Stoker, A.W. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. FEBS J., 2008, 275, 816-30.
95. Tabernero, L.; Aricescu, A.R.; Jones, E.Y.; Szedlacsek, S.E. Protein tyrosine phosphatases: structure-function relationships. FEBS J., 2008, 275, 867-82.
96. Ventura, J.J.; Nebreda, A.R. Protein kinases and phosphatases as therapeutic targets in cancer. Clin. Transl. Oncol., 2006, 8, 153-60.
97. Rye, C.S.; Baell, J.B. Phosphate isosteres in medicinal chemistry. Curr. Med. Chem., 2005, 12, 3127-41.
98. Evdokimov, A.G.; Pokross, M.; Walter, R.; Mekel, M.; Cox, B.; Li, C.; Bechard, R.; Genbauffe, F.; Andrews, R.; Diven, C.; Howard, B.; Rastogi, V.; Gray, J.; Maier, M.; Peters, K.G. Engineering the catalytic domain of human protein tyrosine phosphatase beta for structure-based drug discovery. Acta Crystallogr. D. Biol. Crystallogr., 2006, 62, 1435-45.
99. Grucza, R.A.; Bradshaw, J.M.; Futterer, K.; Waksman, G. SH2 domains: from structure to energetics, a dual approach to the study of structure-function relationships. Med. Res. Rev., 1999, 19, 273-93.
100. Tam, S.; Saiah, E. Recent advances in the discovery and development of PTP-1B inhibitors. Drugs of the future, 2008, 33, 175-185.
101. Salmeen, A.; Andersen, J.N.; Myers, M.P.; Tonks, N.K.; Barford, D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol. Cell, 2000, 6, 1401-12.
102. Iversen, L.F.; Andersen, H.S.; Branner, S.; Mortensen, S.B.; Peters, G.H.; Norris, K.; Olsen, O.H.; Jeppesen, C.B.; Lundt, B.F.; Ripka, W.; Moller, K.B.; Moller, N.P. Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J. Biol. Chem, 2000, 275, 10300-7.
103. Burke, T.R., Jr.; Zhang, Z.Y. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers, 1998, 47, 225-41.
104. Andersen, H.S.; Iversen, L.F.; Jeppesen, C.B.; Branner, S.; Norris, K.; Rasmussen, H.B.; Moller, K.B.; Moller, N.P. 2-(oxalylamino)- benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J. Biol. Chem., 2000, 275, 7101-8.
105. Xie, Y.; Massa, S.M.; Ensslen-Craig, S.E.; Major, D.L.; Yang, T.; Tisi, M.A.; Derevyanny, V.D.; Runge, W.O.; Mehta, B.P.; Moore, L.A.; Brady-Kalnay, S.M.; Longo, F.M. Protein-tyrosine phosphatase (PTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function. J. Biol. Chem., 2006, 281, 16482-92.
106. Alete, D.E.; Weeks, M.E.; Hovanession, A.G.; Hawadle, M.; Stoker, A.W. Cell surface nucleolin on developing muscle is a potential ligand for the axonal receptor protein tyrosine phosphatasesigma. FEBS J., 2006, 273, 4668-81.
107. Aricescu, A.R.; Jones, E.Y. Immunoglobulin superfamily cell adhesion molecules: zippers and signals. Curr. Opin. Cell. Biol., 2007, 19, 543-50.